Darrin Bomba

Mr. Bomba joined Tempest as vice president and head of clinical operations in December 2021. Prior to joining Tempest, Mr. Bomba recently served as executive director, of clinical operations, at CytomX Therapeutics, an oncology-focused biopharmaceutical company, and senior director of clinical operations at Kezar Life Sciences, where he helped establish the company’s clinical development program for two separate assets and oversaw activities leading to the filing of two separate INDs for its lead clinical asset. Mr. Bomba brings over 25 years of industry experience and has held roles of increasing responsibility across all phases of investigational studies and in multiple therapeutic areas, including oncology. In addition to CytomX and Kezar, he has played key roles in leading programs through the complexities of drug development in both large and small pharmaceutical and biotechnology companies, including Amgen/Onyx Pharmaceuticals, Dynavax, Baxter Bioscience, Bristol-Myers Squibb, and Rhone-Poulenc Rorer. Mr. Bomba received a BS in Biomedical Science from Texas A&M University.